Nathiya Muthalagu
Overview
Explore the profile of Nathiya Muthalagu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
907
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Whyte D, Skalka G, Walsh P, Wilczynska A, Paul N, Mitchell C, et al.
Mol Oncol
. 2023 Mar;
17(7):1212-1227.
PMID: 36975767
The AMP-activated protein kinase (AMPK)-related kinase NUAK1 (NUAK family SNF1-like kinase 1) has emerged as a potential vulnerability in MYC-dependent cancer but the biological roles of NUAK1 in different settings...
2.
Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, et al.
Cancer Discov
. 2020 Mar;
10(6):872-887.
PMID: 32200350
MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We...
3.
Bott A, Shen J, Tonelli C, Zhan L, Sivaram N, Jiang Y, et al.
Cell Rep
. 2019 Oct;
29(5):1287-1298.e6.
PMID: 31665640
Glutamine is thought to play an important role in cancer cells by being deaminated via glutaminolysis to α-ketoglutarate (aKG) to fuel the tricarboxylic acid (TCA) cycle. Supporting this notion, aKG...
4.
Muthalagu N, Murphy D
Cell Death Differ
. 2018 May;
25(7):1189-1190.
PMID: 29844569
No abstract available.
5.
Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, et al.
Cancer Discov
. 2018 Mar;
8(5):632-647.
PMID: 29500295
Exploiting oxidative stress has recently emerged as a plausible strategy for treatment of human cancer, and antioxidant defenses are implicated in resistance to chemotherapy and radiotherapy. Targeted suppression of antioxidant...
6.
Farrell A, Joly M, Allen-Petersen B, Worth P, Lanciault C, Sauer D, et al.
Nat Commun
. 2017 Nov;
8(1):1728.
PMID: 29170413
Intratumoral phenotypic heterogeneity has been described in many tumor types, where it can contribute to drug resistance and disease recurrence. We analyzed ductal and neuroendocrine markers in pancreatic ductal adenocarcinoma,...
7.
Sarosiek K, Fraser C, Muthalagu N, Bhola P, Chang W, McBrayer S, et al.
Cancer Cell
. 2016 Dec;
31(1):142-156.
PMID: 28017613
It is not understood why healthy tissues can exhibit varying levels of sensitivity to the same toxic stimuli. Using BH3 profiling, we find that mitochondria of many adult somatic tissues,...
8.
Murphy D, Muthalagu N
Mol Cell Oncol
. 2016 Jun;
2(2):e975083.
PMID: 27308426
In vivo analysis of the genetic determinants of Myc-induced apoptosis reveals a specific requirement for the Bcl2 family protein Bim (Bcl2l11). Surprisingly, apoptosis induced by Myc in multiple solid tissues...
9.
Monteverde T, Muthalagu N, Port J, Murphy D
FEBS J
. 2015 Oct;
282(24):4658-71.
PMID: 26426570
The discovery that the 5'AMP-activated protein kinase (AMPK) serves to link the tumour suppressors LKB1 and the tuberous sclerosis complex and functions to slow macromolecular synthesis through attenuation of the...
10.
Ichim G, Lopez J, Ahmed S, Muthalagu N, Giampazolias E, Delgado M, et al.
Mol Cell
. 2015 Feb;
57(5):860-872.
PMID: 25702873
During apoptosis, the mitochondrial outer membrane is permeabilized, leading to the release of cytochrome c that activates downstream caspases. Mitochondrial outer membrane permeabilization (MOMP) has historically been thought to occur...